IMM2510 plus IMM27M for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two experimental drugs, IMM2510 and IMM27M, for people with advanced hepatocellular carcinoma (a type of liver cancer) that hasn't responded to other treatments. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 75 years old.
- Your liver cancer must be confirmed by a biopsy or cell sample.
- You must be able to care for yourself and be up and about (ECOG score 0 or 1).
- Your liver, kidneys, and bone marrow must be working well enough as determined by doctor's tests.
- You must not have had chemotherapy in the last 4 weeks or other cancers in the last 5 years.
- You must not have current infections needing IV antibiotics, brain tumors causing symptoms, or liver failure-related confusion in the past year.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four treatments (two immunotherapy drugs, a blood-vessel-blocking drug, and chemotherapy delivered directly to the liver) to shrink unresectable (inoperable) advanced liver cancer and potentially make it removable by surgery. The goal is to help patients who have never had cancer treatment before.
This study tests a combination of two immune-based drugs, IMM2510 and IMM27M, for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of cancer.
This trial tests a combination of two experimental drugs, IMM2510 and IMM01, in people with advanced solid tumors that have not responded to other treatments. The goal is to see if the combination can shrink tumors or slow their growth.
This trial tests a combination of two drugs (sintilimab, an immunotherapy, and lenvatinib, a targeted therapy) followed by local treatments to try to cure advanced liver cancer that has spread to a few other parts of the body. The goal is to shrink the cancer enough that surgery or radiation can remove it completely.
This trial tests a new drug called CT-01, either alone or with another drug, for people with intermediate or advanced liver cancer (hepatocellular carcinoma) that has worsened after standard treatments. It might help if you have not responded to or could not tolerate previous therapies.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.